Drug intelligence / Profile preview

DW-4421

Development stage: Phase 1
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW-4421 is a small molecule potassium-competitive acid blocker (P-CAB) being developed by Daewon Pharm for the treatment of gastroesophageal reflux disease (GERD). Unlike traditional proton pump inhibitors (PPIs) that require activation by gastric acid and bind covalently to the H+/K+-ATPase, P-CABs like DW-4421 competitively and reversibly bind to the potassium-binding site of the gastric proton pump. This mechanism allows for a more rapid onset of action, acid-independent activation, and more sustained suppression of gastric acid secretion, potentially addressing the limitations of PPIs such as nocturnal acid breakthrough and slow onset of relief.

Brand names: Dapawon
Other names: metformin + sitagliptin + dapagliflozinMetformin/Sitagliptin/Dapagliflozin FDC

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DW-4421.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-4421.

Explore the full profile